本公司受邀參加台新綜合證券舉辦之法人說明會，說明本公司之營運成果及未來展望。
Agenda as filed by the company, in Chinese only.
PBI (6875) Annual Reports
Listed on the Taipei Exchange (TPEx), classified under Healthcare. This page collects the company's annual reports and investor conference materials, with files served directly by the Market Observation Post System (MOPS).
2
english annual reports
4
english presentations
5
investor conferences
2025
latest year
PBI annual reports
PBI investor conferences
Taiwanese listed companies hold investor conferences (法人說明會) to present quarterly results. Presentation decks are filed with MOPS, most in both languages.
本公司受邀參加凱基證券舉辦之法人說明會，說明本公司之營運概況及未來展望。
Agenda as filed by the company, in Chinese only.
(1)本公司自行開發的吸入伊洛前列素微脂體新藥 L608，憑藉創新研發實力與在臨床試驗中展現的顯著優勢，榮獲 2025 年度歐洲風濕病醫學年會（EULAR Annual European Congress of Rheumatology, EULAR 2025）邀請進行口頭報告。 (2)報告安排於大會「臨床摘要會議：系統性硬化症中的間質性肺部疾病（SSc-ILD）─臨床挑戰與不斷發展的治療方法」專場中，以口頭陳述形式發表最新臨床一期試驗成果。 (3)本公司吸入伊洛前列素微脂體新藥L608臨床一期試驗成果亦獲選為年度臨床科學亮點報告”Highlights from Clinical Science”其中一項臨床試驗，並將由大會於114/06/14報告。 (4)EULAR年會是全球風濕病學領域最具影響力的國際學術盛會之一，由歐洲風濕病聯盟（European Alliance of Associations for Rheumatology, EULAR）主辦，每年吸引超過 18,000 名來自世界各地的臨床醫師、研究人員、產業界與患者代表參與。會議聚焦於風濕病學最新研究進展、臨床挑戰、治療創新與多方合作，為全球風濕病領域提供重要的學術交流與合作平台。 (5)本次獲選不僅彰顯 L608在解決未滿足醫療需求上的創新潛力，也展現本公司於全球創新藥物研發領域的卓越實力與國際學術影響力。本公司期待藉此機會，與全球專家學者深入交流，推動臨床進展，加速實現為病患帶來新型治療選擇的承諾。
Agenda as filed by the company, in Chinese only.
2025-06-11
23:30
(1)本公司自行開發的吸入伊洛前列素微脂體新藥 L608，憑藉創新研發實力與在臨床試驗中展現的顯著優勢，榮獲 2025 年度歐洲風濕病醫學年會（EULAR Annual European Congress of Rheumatology, EULAR 2025）邀請進行口頭報告。 (2)報告安排於大會「臨床摘要會議：系統性硬化症中的間質性肺部疾病（SSc-ILD）─臨床挑戰與不斷發展的治療方法」專場中，以口頭陳述形式發表最新臨床一期試驗成果。 (3)本公司吸入伊洛前列素微脂體新藥L608臨床一期試驗成果亦獲選為年度臨床科學亮點報告”Highlights from Clinical Science”其中一項臨床試驗，並將由大會於114/06/14報告。 (4)EULAR年會是全球風濕病學領域最具影響力的國際學術盛會之一，由歐洲風濕病聯盟（European Alliance of Associations for Rheumatology, EULAR）主辦，每年吸引超過 18,000 名來自世界各地的臨床醫師、研究人員、產業界與患者代表參與。會議聚焦於風濕病學最新研究進展、臨床挑戰、治療創新與多方合作，為全球風濕病領域提供重要的學術交流與合作平台。 (5)本次獲選不僅彰顯 L608在解決未滿足醫療需求上的創新潛力，也展現本公司於全球創新藥物研發領域的卓越實力與國際學術影響力。本公司期待藉此機會，與全球專家學者深入交流，推動臨床進展，加速實現為病患帶來新型治療選擇的承諾。
Agenda as filed by the company, in Chinese only.
本公司受邀參加元富證券舉辦之法人說明會，說明本公司之財務及營運狀況。
Agenda as filed by the company, in Chinese only.
About PBI filings
Where can I download PBI (6875) annual reports?
Every financial year in the table above links straight to the PDF filed with the Market Observation Post System (MOPS), Taiwan's statutory disclosure platform. 2 years are available in English, within a range covering 2024 to 2025.
Why are some years Chinese only?
Filing an English annual report is only mandatory for larger Taiwanese issuers; smaller companies and those on the Emerging Stock Board file in Chinese. Where no English edition exists this site links the Chinese PDF rather than leaving the year blank, so you can still reach the document.
What is an investor conference (法人說明會)?
It is the Taiwanese equivalent of an earnings call or analyst briefing. Listed companies present quarterly results and outlook, and file the presentation deck with MOPS — usually in both Chinese and English. Many also publish a webcast recording.
How does Taiwan's reporting calendar work?
Taiwanese issuers file quarterly financial reports plus an annual report, and publish monthly revenue figures — a disclosure cadence that is more frequent than Hong Kong or Singapore. Financial years are numbered using the ROC calendar (ROC 114 = 2025); this site shows both.
Source: Market Observation Post System (MOPS), Taiwan. All PDF links point to the original
files; nothing is re-hosted here.
Browse all Taiwan listed companies, or read this page in Chinese — the Chinese edition also carries the letter to shareholders and the revenue breakdown.
Browse all Taiwan listed companies, or read this page in Chinese — the Chinese edition also carries the letter to shareholders and the revenue breakdown.